A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001166:Arteriovenous Shunt, Surgical; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000188:drug therapy*; D003645:Death, Sudden; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006350:Heart Valve Prosthesis; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality; D012306:Risk; D013442:Sulfinpyrazone / Q000009:adverse effects / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D004176:Dipyridamole; D001241:Aspirin; D013442:Sulfinpyrazone